|
|
|
By Life Science Connect Editorial Staff | No matter how you approach it, mRNA manufacturing is expensive. The raw materials, technologies, and educated labor force require immense investment. To avoid incurring extra costs and to ensure your strategy is precise and risk averse, identify an experienced partner that prioritizes communication and first-time-right manufacturing. | |
|
|
|
Advancing RNA Live panelists Tyler Goodwin and April Sena start off our latest discussion on technology innovations in mRNA production by surveying the current manufacturing process for plasmid production, highlighting where they’ve seen advancements and what biotechs need to consider to obtain plasmids of the appropriate quality for mRNA production. |
|
|
|
By Louis Johnson | The National Cancer Institute is operating under a continuing resolution that maintains funding at the FY 2024 level of $7.22 billion. But when adjusted for inflation, it effectively reduces the real value of research dollars. So what are the consequences? | |
|
|
|
|
|
|
|
| The Future Of mRNA: Four Key Focuses For Industry | Article | Roche CustomBiotech | Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry. |
|
|
|
|
|
| TIDES USA 2025 | How are industry pioneers accelerating the next wave of therapeutic breakthroughs? Find out at TIDES USA 2025—USA's premier forum for oligonucleotide, peptide, mRNA, genome editing, and drug delivery innovations. May 19-22, 2025 @ Manchester Grand Hyatt San Diego; 150+ expert speakers; 5 tracks & 8 workshops; 1,900+ attendees with networking opportunities; Advanced technology showcases. Save 10% with VERTMARKETS at Checkout. |
|
|
.png){kind=logo}
